Positive Association of US-FLI With the Severity of CAD

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-90
SponsorChongqing Medical University

About this trial

As a multisystem disease, metabolic dysfunction-associated fatty liver disease (MAFLD) is closely linked to the onset and progression of coronary heart disease (CHD). Ultrasonographic fatty liver indicator (US-FLI) is a semi-quantitative tool for evaluating the degree of hepatic steatosis. Our study aims to explore the relationship between US-FLI based on MAFLD and the severity of CHD.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Patients older than 18 years old

Patients underwent ICA due to chest pain, chest tightness or other reasons in our hospital from August 2022 to December 2023 were included in our study

Disqualifiers

Incomplete clinical data

previous coronary stent implantation

no abdominal ultrasound examination

poor ultrasound image quality

Trial population

All research subjects were from the Second Affiliated Hospital of Chongqing Medical University

Trial design

Design model

Case-control

Time perspective

Cross-sectional

Treatments tested in this trial

  • Observational study without human intervention

    Other intervention

    Observational study without human intervention

Treatment groups

190 Participants
are divided into 4 treatment groups
Group A: Non-CAD group0 interventions
Group B: CAD group1 intervention
Group C: SS≤22 group0 interventions
Group D: SS≥23 group1 intervention

Trial outcomes

Primary outcomes

1

SYNTAX score

The complexity of coronary artery disease (CAD) is a predictor of cardiovascular events in patients with \>50 % diameter stenosis as determined by SYNTAX score. The range of US-FLI is 0-8. Fatty liver was diagnosed when US-FLI ≥ 2.

Time frame
at baseline

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.